Literature DB >> 34498339

Knockdown of YKL-40 inhibits angiogenesis through regulation of VEGF/VEGFR2 and ERK1/2 signaling in endometrial cancer.

Hong-Yan Chen1, Zhao-Yu Zhou2, Yan-Lu Luo2, Qin Luo2, Jiang-Tao Fan2.   

Abstract

Studies have demonstrated that small interfering RNA (siRNA) targeting YKL-40 (siYKL-40) inhibits the proliferation, migration, invasion, and induces antiapoptotic abilities of endometrial cancer (EC) HEC-1A cells. However, its effect on angiogenesis is unclear. The present study aimed to investigate the role of YKL-40 in endometrial cancer and the related molecular mechanisms. YKL-40 was knocked down by transfection with siYKL-40 and the effects on angiogenesis, cell viability, and signaling pathways were investigated. The results showed that siYKL-40 inhibited VEGFA levels and tube formation in endothelial cells. Additionally, inhibition of YKL-40 decreased the expression levels of vascular endothelial growth factor (VEGF), phosphorylated vascular endothelial growth factor receptor 2 (pVEGFR2), and phosphorylated extracellular signal-regulated kinases 1 and 2 (pERK1/2). Furthermore, a nude mice xenograft model of EC showed that siYKL-40 inhibited tumor growth. Inhibition of YKL-40 led to suppression of angiogenesis and reduction of microvessel density through VEGF/VEGFR2 and ERK1/2 signaling in endometrial cancer cells. Taken together, this study demonstrated novel molecular mechanisms for role of YKL-40 in EC.
© 2021 International Federation for Cell Biology.

Entities:  

Keywords:  YKL-40; angiogenesis; endometrial cancer; invasion; migration

Mesh:

Substances:

Year:  2021        PMID: 34498339     DOI: 10.1002/cbin.11699

Source DB:  PubMed          Journal:  Cell Biol Int        ISSN: 1065-6995            Impact factor:   3.612


  1 in total

1.  Early reversibility of histological changes after experimental acute cardiac volume-overload.

Authors:  Christa Huuskonen; Mari Hämäläinen; Nooa Kivikangas; Timo Paavonen; Eeva Moilanen; Ari A Mennander
Journal:  Am J Cardiovasc Dis       Date:  2022-08-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.